

LifeSci Biotechnology Clinical Trials Index

3/30/2020

Effective at the market close on Wednesday, April 1, 2020, **RARX** will be removed from the **LifeSci Biotechnology Clinical Trials Index** and its value will be redistributed to the remaining index components based on their weights.

- On October 10, 2019, RA Pharmaceuticals agreed to be acquired by UCB for \$48 per share in cash.